Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Gossamer’s stock sinks after phase 3 pulmonary arterial hypertension fail

Gossamer’s stock sinks after phase 3 pulmonary arterial hypertension fail

  • February 23, 2026

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension has missed its primary endpoint, triggering a 77% crash in the biotech’s share price.

Leave A Comment

Fields (*) Mark are Required